Ashkenazi I, Schermann H, Gold A, et al. - Given the reported association of intraoperative use of tranexamic acid (TXA) with reduction in the administration of allogenic blood transfusion in total joint arthroplasty (TJA) patients, researchers here examined the efficacy and safety of intraoperative TXA use in cases undergoing hip hemiarthroplasty as treatment for intracapsular femoral neck fracture. In this historical cohort of 1,722 consecutive patients (601 males and 1,121 females) who underwent hip hemiarthroplasty between 2011 and 2019, 504 were in the "TXA" group and 1,218 were in the "non-TXA" group. Outcomes suggest that in line with the known effect of TXA in TJA patients, the use of TXA treatment in cases undergoing hip hemiarthroplasty resulted in a significant decrease in 30-day mortality, in postoperative blood loss and in the proportion of cases necessitating allogenic blood transfusions.